Clinical Trials Sponsored by Immune Pharmaceuticals

Total 20012 results

Immune Pharmaceuticals

Unknown

Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

Israel
Immune Pharmaceuticals

Completed

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

Pemphigoid, Bullous

United States, Israel
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Tasly Pharmaceuticals, Inc.
Natural Immune Systems Inc

Unknown

Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control

Glucose Metabolism Disorders

United States
Immune Design

Terminated

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Melanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Immune Control

Unknown

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Multiple Myeloma

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Immune Design

Completed

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States
Immune Design

Completed

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Melanoma | Sarcoma | Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Regeneron Pharmaceuticals
Sanofi; Aimmune Therapeutics, Inc.

Completed

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Peanut Allergy

United States
Smart Immune SAS

Recruiting

Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors (SMART101-HV1)

Healthy Volunteers

France
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Repertoire Immune Medicines

Terminated

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Melanoma | Cervical Cancer | Head and Neck Squamous Cell Carcinoma

United States
Repertoire Immune Medicines

Terminated

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Melanoma | Head and Neck Cancer | HPV-Related Malignancy | Melanoma (Skin) | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Lung Cancer, Nonsmall Cell

United States
AC Immune SA

Withdrawn

A Study of ACI-24 in Adults With Down Syndrome

Down Syndrome
Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Smart Immune SAS

Recruiting

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Hematological Malignancies

France
Immune-Onc Therapeutics

Recruiting

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Smart Immune SAS

Recruiting

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Hematological Malignancies

United States
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Immune Oncology Research Institute

Recruiting

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Pediatric Cancer

Armenia
Natural Immune Systems Inc

Recruiting

Clinical Proof-of-concept Study on Immune Surveillance and Alertness

Immune Surveillance

United States
Natural Immune Systems Inc

Recruiting

Antioxidant Bioavailability

Pharmacokinetics

United States
Immune System Regulation AB

Unknown

Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

HIV-1-infection

Sweden, Germany
Immune System Key Ltd

Withdrawn

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Israel
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Natural Immune Systems Inc

Completed

Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function

Fatigue

United States
Natural Immune Systems Inc

Completed

Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness. (114-012)

Range of Motion

United States
Natural Immune Systems Inc

Completed

CytoQuel: Clinical Documentation on Effects on Chronic Pain, Wellness, and Reduction of Inflammatory Markers

Pain

United States
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States, Canada, Australia, Turkey
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of
Noile-Immune Biotech, Inc

Recruiting

Study of NIB101 in Participants With Advanced Solid Tumors

Solid Tumor

Japan
Natural Immune Systems Inc

Recruiting

Immunological Effect of Increasing Doses of Natural Peptide

Pharmacokinetics

United States
Natural Immune Systems Inc

Recruiting

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

Pharmacokinetics

United States
Immune Response BioPharma, Inc.

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Multiple Sclerosis

United States
Alpine Immune Sciences, Inc.

Active, not recruiting

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus (Synergy)

Systemic Lupus Erythematosus

United States, France, Hungary, Poland, Puerto Rico, Spain, Taiwan
NeoImmuneTech
Immune Oncology Network

Terminated

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Melanoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Alpine Immune Sciences, Inc.

Terminated

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD (Balance)

Graft Vs Host Disease

United States
Immune System Key Ltd

Withdrawn

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Triple Negative Breast Cancer | Metastatic Ovarian Cancer

Israel
Immune System Key Ltd

Completed

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

Cancer

Israel
Immune Response BioPharma, Inc.

Unknown

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

HIV/AIDS

United States
Natural Immune Systems Inc

Completed

Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population

Anemia

United States
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Immune Technologies & Medicine GmbH

Unknown

Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis

Psoriasis

Switzerland
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease

3

Subscribe